Abigail E. Mitchell, Heather M. Colvin, R. Palmer Beasley – 22 February 2010 – Despite federal, state, and local public health efforts to prevent and control hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, these diseases remain serious health problems in the United States. About 1%‐2% of the U.S. population has chronic HBV or HCV infections, and each year about 15,000 people die from liver cancer or liver disease related to these preventable infections.

Ali Raza, George Dikdan, Kunj K. Desai, Asif Shareef, Helen Fernandes, Virginie Aris, Andrew N. de la Torre, Dorian Wilson, Adrian Fisher, Patricia Soteropoulos, Baburao Koneru – 19 February 2010 – The benefits of ischemic preconditioning (IPC) in reducing ischemia/reperfusion injury (IRI) remain indistinct in human liver transplantation (LT). To further understand mechanistic aspects of IPC, we performed microarray analyses as a nested substudy in a randomized trial of 10‐minute IPC in 101 deceased donor LTs.

Timothy J. S. Cross, Andrew K. Burroughs, Phillip M. Harrison – 19 February 2010

Keishi Sugimachi, Ken Shirabe, Akinobu Taketomi, Yuji Soejima, Tomoharu Yoshizumi, Yo‐Ichi Yamashita, Kenji Umeda, Kazutoyo Morita, Yoshihiko Maehara – 19 February 2010

Woo Young Shin, Kyung‐Suk Suh, Hae Won Lee, Joohyun Kim, Taehoon Kim, Nam‐Joon Yi, Kuhn Uk Lee – 12 February 2010 – Liver transplantation is regarded as an effective treatment for early hepatocellular carcinoma (HCC). However, some patients experience recurrence and subsequently rapid progression of the disease. We investigated prognostic factors affecting survival after recurrence in patients who underwent adult living donor liver transplantation (LDLT) for HCC. From October 1992 to December 2005, 138 adult patients underwent LDLT for HCC.

Ronald W. Busuttil – 12 February 2010

Zeeshan Butt,, Daniela Ladner, Neehar Parikh – 8 February 2010

Fabio Piscaglia, Alice Gianstefani, Matteo Ravaioli, Rita Golfieri, Alberta Cappelli, Emanuela Giampalma, Elisabetta Sagrini, Grazia Imbriaco, Antonio Daniele Pinna, Luigi Bolondi – 8 February 2010 – Malignant portal vein thrombosis is a contraindication for liver transplantation. Patients with cirrhosis and early hepatocellular carcinoma (HCC) may have either malignant or benign (fibrin clot) portal vein thrombosis.

Franklin Greif, Ziv Ben‐Ari, Rasim Taya, Orit Pappo, Efrat Kurtzwald, Yelena Cheporko, Amiram Ravid, Edith Hochhauser – 8 February 2010 – The only currently offered curative option for many patients with primary or secondary liver tumors is the resection of hepatic tumors. The aim of this study was to evaluate the role of recombinant human erythropoietin (rhEPO) in liver protection and regeneration after subtotal hepatectomy in rats. Rats undergoing 70% hepatectomy received an intraperitoneal injection of saline (control) or rhEPO (4 U/g) 30 minutes prior to resection.

John F. Renz – 8 February 2010